UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 607

Sortiert nach

Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome

Proceedings of the National Academy of Sciences - PNAS, 2012-10, Vol.109 (41), p.16666-16671

2012

Volltextzugriff (PDF)

Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway

Oncogene, 2002-04, Vol.21 (17), p.2613-2622

2002

Volltextzugriff (PDF)

Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression

Oncogene, 2003-06, Vol.22 (23), p.3645-3654

2003

Volltextzugriff (PDF)

Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti–IGF-IR antibody

Molecular cancer therapeutics, 2005-08, Vol.4 (8), p.1214-1221

2005

Volltextzugriff (PDF)

Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies

American journal of medical genetics. Part C, Seminars in medical genetics, 2011-05, Vol.157C (2), p.136-146

2011

Volltextzugriff (PDF)

Neutralizing Anti-Insulin-like Growth Factor Receptor 1 Antibodies Inhibit Receptor Function and Induce Receptor Degradation in Tumor Cells

Molecular cancer therapeutics, 2002-12, Vol.1 (14), p.1349

2002

Volltextzugriff (PDF)

Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors

Clinical cancer research, 2004-05, Vol.10 (9), p.2968-2976

2004

Volltextzugriff (PDF)

SCH529074, a Small Molecule Activator of Mutant p53, Which Binds p53 DNA Binding Domain (DBD), Restores Growth-suppressive Function to Mutant p53 and Interrupts HDM2-mediated Ubiquitination of Wild Type p53

The Journal of biological chemistry, 2010-04, Vol.285 (14), p.10198-10212

2010

Volltextzugriff (PDF)

Integrative Genomics Revealed RAI3 Is a Cell Growth-promoting Gene and a Novel P53 Transcriptional Target

The Journal of biological chemistry, 2005-04, Vol.280 (13), p.12935-12943

2005

Volltextzugriff (PDF)

A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts

Molecular cancer therapeutics, 2010-02, Vol.9 (2), p.410-418

2010

Volltextzugriff (PDF)

The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity

The Journal of biological chemistry, 2005-09, Vol.280 (35), p.31101-31108

2005

Volltextzugriff (PDF)

Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336)

Anti-cancer drugs, 2007-09, Vol.18 (8), p.923-931

2007

Volltextzugriff (PDF)

Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy

Drug resistance updates, 2003-08, Vol.6 (4), p.183-195

2003

Volltextzugriff (PDF)

Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules

The Journal of biological chemistry, 2000-09, Vol.275 (39), p.30451-30457

2000

Volltextzugriff (PDF)

K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors

The Journal of biological chemistry, 1997-05, Vol.272 (22), p.14459-14464

1997

Volltextzugriff (PDF)

Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors

ACS medicinal chemistry letters, 2016-03, Vol.7 (3), p.324-329

2016

Volltextzugriff (PDF)

Identification and Characterization of Zinc Binding Sites in Protein Kinase C

Science (American Association for the Advancement of Science), 1991-12, Vol.254 (5039), p.1776-1779

1991

Volltextzugriff (PDF)

Impact of Farnesylation Inhibitors on Survival in Hutchinson-Gilford Progeria Syndrome

Circulation (New York, N.Y.), 2014-07, Vol.130 (1), p.27-34

2014

Volltextzugriff (PDF)

Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells

Molecular cancer therapeutics, 2003-03, Vol.2 (3), p.219-224

2003

Volltextzugriff (PDF)

Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in Vitro Substrates for Farnesyl Protein Transferase and Geranylgeranyl Protein Transferase Type I

The Journal of biological chemistry, 1997-04, Vol.272 (15), p.10232-10239

1997

Volltextzugriff (PDF)

Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models

International journal of cancer, 2009-12, Vol.125 (11), p.2711-2720

2009

Volltextzugriff (PDF)

Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo

Gynecologic oncology, 2008-04, Vol.109 (1), p.97-106

2008

Volltextzugriff (PDF)

Discovery of C-imidazole azaheptapyridine FPT inhibitors

Bioorganic & medicinal chemistry letters, 2010-02, Vol.20 (3), p.1134-1136

2010

Volltextzugriff (PDF)

1 – 25 von 607

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(531)
Mit Volltextzugriff
(541)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(396)
Life Sciences & Biomedicine
(327)
Humans
(257)
Female
(139)
Male
(127)
Biological And Medical Sciences
(109)
Animals
(102)
Medical Sciences
(84)
Adult
(80)
Middle Aged
(70)
Oncology
(52)
Biochemistry & Molecular Biology
(50)
Aged
(49)
Physical Sciences
(49)
Mice
(45)
Science & Technology - Other Topics
(42)
Multidisciplinary Sciences
(41)
Orthopedics
(39)
Pharmacology & Pharmacy
(38)
Risk Factors
(37)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors

Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway

Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression

Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti–IGF-IR antibody

Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies

Neutralizing Anti-Insulin-like Growth Factor Receptor 1 Antibodies Inhibit Receptor Function and Induce Receptor Degradation in Tumor Cells

Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors

SCH529074, a Small Molecule Activator of Mutant p53, Which Binds p53 DNA Binding Domain (DBD), Restores Growth-suppressive Function to Mutant p53 and Interrupts HDM2-mediated Ubiquitination of Wild Type p53

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors

Integrative Genomics Revealed RAI3 Is a Cell Growth-promoting Gene and a Novel P53 Transcriptional Target

A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts

The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity

Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336)

Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy

Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules

K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors

Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors

Identification and Characterization of Zinc Binding Sites in Protein Kinase C

Impact of Farnesylation Inhibitors on Survival in Hutchinson-Gilford Progeria Syndrome

Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells

Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in Vitro Substrates for Farnesyl Protein Transferase and Geranylgeranyl Protein Transferase Type I

Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models

Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo

Discovery of C-imidazole azaheptapyridine FPT inhibitors

Suchergebnisse filtern